HOSPIRA, INC. | MedPath

Gland Pharma Secures USFDA Approval for Acetaminophen Injection for Pain Management

2 months ago

• Gland Pharma has received USFDA approval for Acetaminophen Injection (10 mg/mL) in 500mg/50mL and 1000mg/100mL bag formulations for pain management. • The injectable product is indicated for mild to moderate pain management in patients 2 years and older, and for moderate to severe pain when used with opioid analgesics. • With US sales of approximately $55 million for the twelve months ending February 2025, Gland Pharma plans to launch the product through a marketing partner soon.

Glenmark Launches Generic Epinephrine Injection with 180-Day Exclusivity

3 months ago

• Glenmark Pharmaceuticals has launched a generic version of Epinephrine Injection USP (10 mg/10 mL) Multiple-Dose Vial, securing 180 days of competitive generic therapy exclusivity. • The product is bioequivalent to BPI Labs' reference drug and enters a market with annual sales of approximately $42.7 million as of December 2024. • This strategic launch expands Glenmark's institutional channel portfolio, reinforcing their commitment to providing affordable treatment alternatives.

Glenmark Pharmaceuticals Launches Phytonadione Injectable Emulsion for Blood Clotting Issues

4 months ago

Glenmark Pharmaceuticals' US arm has launched Phytonadione Injectable Emulsion USP, 10mg/ml, a treatment for blood clotting problems caused by Vitamin K deficiency. The drug is bioequivalent and therapeutically equivalent to Hospira's Vitamin K Injectable Emulsion. Additionally, Glenmark reported promising Phase 1 clinical trial results for its Trispecific TREAT Antibody, ISB 2001, in treating Multiple Myeloma.

Gland Pharma Receives US FDA Approval for Phytonadione Injectable Emulsion

5 months ago

• Gland Pharma has secured US FDA approval for its phytonadione injectable emulsion, a generic version of vitamin K1 injectable emulsion. • The drug is indicated for treating coagulation disorders resulting from vitamin K deficiency or interference with vitamin K activity. • The company plans to launch the product through its marketing partners, with US sales for the reference drug estimated at $15 million annually. • Gland Pharma's stock experienced a rally following the announcement, reflecting positive market sentiment.